The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
Ryght AI tackles these hurdles with its AI Site Twin platform
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
Roche says its new assay “resolves this challenge by delivering accurate and specific results
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Patients can now get the starting 2.5 mg dose for $299 per month
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
Subscribe To Our Newsletter & Stay Updated
